Virulence (Dec 2023)

Evaluation of the safety, immunogenicity and efficacy of a new live-attenuated lumpy skin disease vaccine in India

  • Naveen Kumar,
  • Sanjay Barua,
  • Ram Kumar,
  • Nitin Khandelwal,
  • Amit Kumar,
  • Assim Verma,
  • Lokender Singh,
  • Bhagraj Godara,
  • Yogesh Chander,
  • Garvit Kumar,
  • Thachamvally Riyesh,
  • Deepak Kumar Sharma,
  • Anubha Pathak,
  • Sanjay Kumar,
  • Ramesh Kumar Dedar,
  • Vishal Mehta,
  • Mitesh Gaur,
  • Bhupendra Bhardwaj,
  • Vithilesh Vyas,
  • Sarjeet Chaudhary,
  • Vijaypal Yadav,
  • Adrish Bhati,
  • Rakesh Kaul,
  • Arif Bashir,
  • Anjum Andrabi,
  • Raja Wasim Yousuf,
  • Abhimanyu Koul,
  • Subhash Kachhawaha,
  • Amol Gurav,
  • Siddharth Gautam,
  • Hari Audh Tiwari,
  • Vijay Kumar Munjal,
  • Madhurendu K. Gupta,
  • Rajender Kumar,
  • Baldev R. Gulati,
  • Jyoti Misri,
  • Ashok Kumar,
  • Ashok Kumar Mohanty,
  • Sukdeb Nandi,
  • Karam Pal Singh,
  • Yash Pal,
  • Triveni Dutt,
  • Bhupendra N. Tripathi

DOI
https://doi.org/10.1080/21505594.2023.2190647
Journal volume & issue
Vol. 14, no. 1

Abstract

Read online

ABSTRACTLumpy skin disease (LSD) was reported for the first time in India in 2019 and since then, it has become endemic. Since a homologous (LSD-virus based) vaccine was not available in the country, goatpox virus (GPV)-based heterologous vaccine was authorized for mass immunization to induce protection against LSD in cattle. This study describes the evaluation of safety, immunogenicity and efficacy of a new live-attenuated LSD vaccine developed by using an Indian field strain, isolated in 2019 from cattle. The virus was attenuated by continuous passage (P = 50) in Vero cells. The vaccine (50th LSDV passage in Vero cells, named as Lumpi-ProVacInd) did not induce any local or systemic reaction upon its experimental inoculation in calves (n = 10). At day 30 post-vaccination (pv), the vaccinated animals were shown to develop antibody- and cell-mediated immune responses and exhibited complete protection upon virulent LSDV challenge. A minimum Neethling response (0.018% animals; 5 out of 26,940 animals) of the vaccine was observed in the field trials conducted in 26,940 animals. There was no significant reduction in the milk yield in lactating animals (n = 10108), besides there was no abortion or any other reproductive disorder in the pregnant animals (n = 2889). Sero-conversion was observed in 85.18% animals in the field by day 30 pv.

Keywords